Active Health Studies

UW Veterinary Care at the University of Madison is Looking for Dogs with Cancer

 

Phase I clinical trial to evaluate the biological effective dose and  tolerability of trametinib in dogs with cancer

THE STUDY
We are studying a novel drug called Trametinib, an FDA-approved drug for the treatment of people with melanoma, for the treatment of cancer in dogs. Previous research showed trametinib to be highly effective against canine histiocytic sarcoma. Differently from conventional chemotherapies, trametinib blocks specific factors that cancer cells use to continue multiplying and surviving. The goal of this study is to evaluate the effects of this drug on the tumor and its safety profile in dogs with cancer.

 

WHO QUALIFIES
Dogs with any type of cancer that are not currently receiving chemotherapy.

 

WHAT HAPPENS
Dogs will receive trametinib orally once a day on an outpatient basis. Sample collections will be performed during the first week of treatment. Patients will then be evaluated every 3 weeks after the start of treatment. Owners will be asked to complete questionnaires throughout the duration of the study.


WHY PARTICIPATE
The study will allow us to evaluate the effect and tolerability of trametinib in dogs with cancer. The ultimate goal of this study is to define the role of trametinib as a novel targeted therapy for dogs with histiocytic sarcoma, improving their outcome and survival. Dogs with other types of cancer will likely benefit from trametinib as well. The drug itself, as well as recheck physical exams and blood work will be paid for by the study.

 

MORE INFORMATION
Please contact Marilia Takada, DVM, MS, PhD at takada@wisc.edu; David Vail, DVM, DACVIM (Onc) at david.vail@wisc.edu; or Amanda Brooks, CVT at simons5@wisc.edu for more informatio
n.

Bloat/GDV (Gastric Dilation Volvulus) Submissions

We have had a researcher request samples from the BMD Repository at Michigan State University from dogs that were “diagnosed” with Bloat / GDV (Gastric Dilation Volvulus), for his upcoming research study on GDV.


IMPORTANT-- If your Berner (living or deceased) has a blood or cheek swab DNA sample in the BMD Repository and has experienced a Bloat/GDV event, please be sure that information is added to your dogs Berner-Garde health record. It is important to make these updates as soon as you can! If you are able to get information from your vet that would allow this information to be entered into the database as "diagnosed", that would be extremely helpful for this research effort, as it will enable us to provide diagnosed GDV samples to the researcher for this important project.


We also need “anecdotal” bloat/GDV information on dogs that have blood and cheek swab samples in the BMD Repository as well, as this is also very important for us to have for re-searchers, and to help us to identify control dogs for this and future GDV studies. Even if your dog does not have DNA samples in the Repository, please update any Bloat/GDV information into the Berner-Garde Database for future research studies as well.


Our Berner-Garde site operators are ready to receive and verify your dog’s Bloat/GDV information updates now. And a re-minder about the importance of updating your dogs health record in Berner-Garde, especially date and cause of death information. This is important for any dogs in the database, but especially critical for dogs with DNA samples in the Repository!


If you need help entering updated information on your dog, please contact me (see contact info below).


Thank you so much for your help!
Brycie Marine
Berner-Garde Trustee
Co-Liaison to the BMD Repository at MSU
E-mail: lbmarin@new.rr.com

  • Facebook Social Icon
This site was designed with the
.com
website builder. Create your website today.
Start Now